Trial Profile

Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; Cytokine release syndrome; Pneumonia
Focus Expanded access; Therapeutic Use

Most Recent Events

15 Jan 2021 Status changed from suspended to discontinued as randomized data no longer support continuation.
11 Aug 2020 Planned End Date changed from 1 Nov 2021 to 1 Apr 2022.
11 Aug 2020 Planned primary completion date changed from 1 Nov 2021 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com